AFC-HD AMS Life Science Co., Ltd.

As of February 28, 2026, AFC-HD AMS Life Science Co., Ltd. carries a market capitalization of 13.21B, placing it among publicly traded companies globally. Its enterprise value stands at 26.07B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

AFC-HD AMS Life Science Co., Ltd.'s next confirmed earnings release is scheduled for January 8, 2027.

As of February 28, 2026, AFC-HD AMS Life Science Co., Ltd. has 14.56M shares outstanding.

These figures are as of February 28, 2026.

As of February 28, 2026, AFC-HD AMS Life Science Co., Ltd. maintains a current ratio of 0.85, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended February 28, 2026.

As of the close on October 22, 2026, AFC-HD AMS Life Science Co., Ltd.'s stock has declined approximately 1.83% over the past 52 weeks. The 50-day moving average sits at 864.56, while the 200-day moving average is 869.31.

As of February 28, 2026, AFC-HD AMS Life Science Co., Ltd. holds 11.09B in cash and equivalents against 23.76B in total debt, resulting in a net debt position of 12.67B. Total book value stands at 16.03B, with working capital of -3.93B providing operational flexibility.

AFC-HD AMS Life Science Co., Ltd.'s most recent stock split took place on August 29, 2011 with a 1:10 split ratio.